CGEN

CompugenB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-23

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$3.20

+36.8% vs current

Most likely

Base case

45%

Probability

Target price

$2.10

-10.3% vs current

B-

Bear case

30%

Probability

Target price

$1.10

-53.0% vs current

AI sentiment snapshot

Latest data as of 2026-06-18

AI commentary

Primary-source support improved after confirming the May 18, 2026 Form 6-K and furnished company press release, which directly support the runway, spend, and Q1 2027 interim-timing claims [#SEC-6K-2026-05-18] [#PR-2026-05-18]. Even so, this remains a low-coverage small-cap biotech monitoring setup with limited verified post-print analyst reaction and no trustworthy primary-source evidence of a broader thesis change since the Q1 release.

RankAlpha Sentiment Codex - 2026-06-18

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-18catalystQ1 2026 results kept the story in monitoring modeMedium impact

Compugen's May 18, 2026 Form 6-K and attached Exhibit 99.1 showed roughly $2.2 million of Q1 revenue, R&D expense rising to about $6.9 million mainly from MAIA-ovarian and drug-supply costs, and net loss of about $7.7 million, which supports a cautious read rather than a near-term operating inflection [#SEC-6K-2026-05-18] [#PR-2026-05-18].

2026-12-31catalystRunway into 2029 lowers financing pressure while partnered assets advanceHigh impact

Compugen reported about $134.9 million in cash, cash equivalents, deposits, and marketable securities as of March 31, 2026, said that should fund operations into 2029 with no debt, and highlighted continued progress for AstraZeneca-partnered rilvegostomig and Gilead-partnered GS-0321; that extends time for pipeline execution but does not remove clinical risk [#PR-2026-05-18].

2027-03-31eventMAIA-ovarian interim analysis is the main valuation resetHigh impact

The company said COM701 MAIA-ovarian is actively enrolling across the U.S., Israel, and France and remains on track to have median progression-free survival at the interim analysis by Q1 2027, making this the clearest binary catalyst for the stock [#PR-2026-05-18].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-18 • Updated nightlySource: Internal modelMethodology